iproniazid has been researched along with Parkinson Disease in 9 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Matos, MJ | 1 |
| Viña, D | 1 |
| Picciau, C | 1 |
| Orallo, F | 1 |
| Santana, L | 1 |
| Uriarte, E | 1 |
| Distinto, S | 1 |
| Yáñez, M | 1 |
| Alcaro, S | 1 |
| Cardia, MC | 1 |
| Gaspari, M | 1 |
| Sanna, ML | 1 |
| Meleddu, R | 1 |
| Ortuso, F | 1 |
| Kirchmair, J | 1 |
| Markt, P | 1 |
| Bolasco, A | 1 |
| Wolber, G | 1 |
| Secci, D | 1 |
| Maccioni, E | 1 |
| Wang, Z | 1 |
| Wu, J | 1 |
| Yang, X | 1 |
| Cai, P | 1 |
| Liu, Q | 1 |
| Wang, KDG | 1 |
| Kong, L | 1 |
| Wang, X | 1 |
| Elzien Alamin Ali, H | 1 |
| Ozalp, L | 1 |
| Danış, Ö | 1 |
| Odabaş, Z | 1 |
| SIGWALD, J | 1 |
| Hassler, R | 1 |
| Gorkin, VZ | 1 |
| Ernst, AM | 1 |
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
1 review available for iproniazid and Parkinson Disease
| Article | Year |
|---|---|
[New data on monoamine oxidase inhibitors].
Topics: Acridines; Animals; Brain; Cytoplasm; Hydrazines; Iproniazid; Isoquinolines; Liver; Membranes; Mitoc | 1971 |
8 other studies available for iproniazid and Parkinson Disease
| Article | Year |
|---|---|
Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.
Topics: Coumarins; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Isofo | 2009 |
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dyn | 2012 |
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Mice; Mice, Inbred S | 2016 |
Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
Topics: Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Dis | 2022 |
[Treatment of parkinsonian akinesia].
Topics: Apraxias; Humans; Imipramine; Iproniazid; Monoamine Oxidase Inhibitors; Parkinson Disease | 1961 |
[Correlations between chemical mediators (dopamine, serotonin, acetylcholine and gaba), muscular tone and rapidity of movement].
Topics: 5-Hydroxytryptophan; Acetylcholine; Alkaloids; Aminobutyrates; Animals; Dihydroxyphenylalanine; Dopa | 1972 |
Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats.
Topics: Animals; Apomorphine; Chemistry, Pharmaceutical; Compulsive Behavior; Dextroamphetamine; Dihydroxyph | 1967 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |